KPIs & Operating Metrics(New)
Growth Metrics

Chemed (CHE) Common Equity (2016 - 2026)

Chemed filings provide 18 years of Common Equity readings, the most recent being $848.0 million for Q1 2026.

  • For the quarter ending Q1 2026, Common Equity fell 28.24% year-over-year to $848.0 million, compared with a TTM value of $848.0 million through Mar 2026, down 28.24%, and an annual FY2025 reading of $979.4 million, down 12.47% over the prior year.
  • Common Equity hit $848.0 million in Q1 2026 for Chemed, down from $979.4 million in the prior quarter.
  • The five-year high for Common Equity was $1.2 billion in Q3 2024, with the low at $666.7 million in Q1 2022.
  • Median Common Equity over the past 5 years was $1.0 billion (2023), compared with a mean of $991.8 million.
  • The sharpest move saw Common Equity soared 41.28% in 2023, then fell 28.24% in 2026.
  • Year by year, Common Equity stood at $798.7 million in 2022, then soared by 38.71% to $1.1 billion in 2023, then rose by 1.0% to $1.1 billion in 2024, then dropped by 12.47% to $979.4 million in 2025, then decreased by 13.42% to $848.0 million in 2026.
  • According to Business Quant data, Common Equity over the past three periods came in at $848.0 million, $979.4 million, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.